Arcutis Biotherapeutics Inc (ARQT) Return on Investment ROI from the third quarter of 2026 to third quarter of 2025 and for the year 2026, average high and low, overall ranking from Sep 30 2026 to Sep 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Arcutis Biotherapeutics Inc   (NASDAQ: ARQT)


Arcutis Biotherapeutics Inc's ROI from its third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Arcutis Biotherapeutics Inc's ROI in the third quarter of 2026?
Arcutis Biotherapeutics Inc achieved a return on average invested assets (ROI) of 17.54 % in its third quarter of 2026, this is above ARQT's average return on investment of -28.74%.
Arcutis Biotherapeutics Inc invested over the 12 months ending in its third quarter of 2026 $321 million

ROI decreased relative to the period ending Jun 30 2026, due to the decline in net income.

Within the Healthcare sector 50 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the second quarter of 2026 from 1350 to 1387.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter
Y / Y Investment Change TTM 23.45 % 16.25 % -5.17 % -20.86 % -24.94 %
Y / Y Net Income Change TTM -69.78 % -29.28 % -84.32 % -84.54 % -
Investment (TTM) in Millions 353 329 297 303 271
Return On Investment (TTM) 17.54 % 20.77 % 5.84 % 6.01 % 71.66 %
ARQT's Overall Ranking # 1387 # 1350 # 43 # 112 #
Seq. Investment Change TTM 6.84 % 7.37 % 4.08 % 3.39 % 0.61 %
Seq. Net Income Change TTM -9.78 % 282.18 % 1.15 % -91.33 % 111.11 %
Net Income (TTM) in Millions 56 62 16 16 186

ARQT Company Profile >> Back to ARQT Roi Comparisons >> See Annual ARQT Return On Investment



Return On Investment ARQT's Ranking
Within: No.
Industry # 26
Sector # 51
Overall # 1387

Return On Investment Statistics
High Average Low
71.66 %
-28.74 %
-87.65 %
(Sep 30 2025)   (Jun 30 2023)







Financial Statements
Arcutis Biotherapeutics Inc's III. Quarter Investments $ 353 Millions ARQT's Balance sheet
Arcutis Biotherapeutics Inc's III. Quarter Income $ 9 Millions Quarterly ARQT's Income Statement
ARQT's Income by Division See ARQT's Income by Division


ARQT Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 303 268 295 411 375
Y / Y Investment Growth 13.16 % -9.1 % -28.38 % 9.78 % 35.97 %
Net Income in Millions -1 -1 -3 -311 -206
Y / Y Net Income Growth - - - - -
Annual Return On Investment -0.39 % -0.24 % -1.06 % -75.69 % -55.05 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
ARQT's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for ARQT's Competitors
Subscribers only: Roi for Arcutis Biotherapeutics Inc's Suppliers
Subscribers only: Return On Investment for ARQT's Customers

Other Ratios
ARQT's Roa ARQT's Inventory Turnover Ratio ARQT's Growth Rates ARQT's Dividend Statistics
ARQT's Profitability Ratios ARQT's Asset Turnover Ratio ARQT's Dividend Growth
ARQT's Roe ARQT's Valuation Ratios ARQT's Financial Strength Ratios ARQT's Dividend Payout Ratio



Companies with similar Return On Investment at Sep 30 2026, within Healthcare Sector ROI
Aurinia Pharmaceuticals Inc   45.04 %
Nurix Therapeutics Inc   44.12 %
Medpace Holdings Inc   41.14 %
Rallybio Corporation  36.04 %
Eli Lilly And Company  32.00 %
Caredx Inc   30.65 %
Zevra Therapeutics Inc   29.88 %
Acadia Pharmaceuticals Inc   26.89 %
Protalix Biotherapeutics inc   26.06 %
Standard Biotools Inc   23.91 %
Electromed Inc   23.41 %
Iradimed Corporation  22.98 %
Corcept Therapeutics Inc  22.08 %
Resmed Inc   21.10 %
Alector Inc   20.83 %
Chemed Corporation  20.46 %
Halozyme Therapeutics Inc   19.64 %
Pro dex Inc   19.11 %
Dexcom Inc   18.92 %
Illumina Inc   18.74 %
Denali Therapeutics Inc   17.88 %
West Pharmaceutical Services Inc   17.65 %
Healthcare Services Group Inc   17.18 %
Neurocrine Biosciences Inc   16.94 %
Krystal Biotech Inc   16.91 %
Vertex Pharmaceuticals Inc  16.63 %
Sanuwave Health Inc   16.50 %
Intuitive Surgical Inc   16.30 %
Hca Healthcare Inc   15.54 %
Kiniksa Pharmaceuticals International Plc  15.45 %

Date modified: 2026-11-07T13:24:31+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.